Druggability Enabling High Throughput NanoActive™ Technology Platform - from drug discovery to production
|
NanGenex’s mission is to develop proprietary nanodrugs with fundamental improvements and clinically meaningful benefits over traditional drug formulations. NanGenex’s Druggability Enabling High Throughput NanoActive™ Technology Platform introduces a paradigm shift in drug discovery, development and manufacturing. NanGenex’s complex and integrated intelligent platform approach can generate drugable active compounds in a high throughput fashion and build up a critical mass of nano-transformation knowledge base that is unrivalled by alternative technologies. The Company’s Druggability Enabling NanoActive™ High Throughput Technology Platform enables the development of proprietary NanoDrug formulations directed at existing or newly developed chemical entities getting over the failures and shortcomings of the commercially available top-down milling and high pressure homogenization based technologies. NanoActive™ formulations have the ability to transform multiple physico-chemical properties enabling successful oral administration of drugs with challenging profiles as well as enabling utilization of previously unutilizable alternative routes of administration, such as pulmonary, transdermal, inhalational, buccal, and intravenous. The Druggability Enabling NanoActive™ High Throughput Technology Platform is a bottom-up, continuous flow, nano-precipitation based technology platform with the demonstrated capability of delivering unique particle properties through precise control and optimization of multiple transformation parameters. The platform enables also the creation of nanostructured pharmaceutical macromolecules (e.g. polypeptides, polynucleotides) and highly stable nanostructured particles for prolonged release to extend the half life of the drugs. The intelligent Technology Platform includes the prediction of the optimal nanoformulation parameters using NanGenex’s searchable database and supports nano Structure-Activity Relationship (NanoSAR) calculations. The NanoActive technology allows us to tailor the properties of the nanostructured active compounds by the precise process control (e.g. temperature, flow rate and pH), while the integrated on-line analytics helps shorten the parameter optimization loop to reach the desired particle size. The GMP compliant instrument lines can produce nanostructured actives from 20 mgs to 2-4 kilograms daily with excellent parameter control and reproducibility. NanGenex has now had in depth experience in moving a compound from API to the confirmation of druggable candidate formulations and on to the successful execution of pre-clinical studies. |
High Throughput NanoActive™ Laboratory
Druggability Enabling High Throughput NanoActive™ Technology Platform includes
|
